サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1546126

デング熱ワクチンの市場規模：ワクチンタイプ・ ワクチンフェーズ・流通チャネル・地域別の展望・競合戦略・セグメント予測 (～2033年)

Dengue Vaccines Market Size- By Type of Vaccine, By Vaccine Phase, By Distribution Channel- Regional outlook, Competitive Strategies and Segment Forecast to 2033

出版日
ページ情報
英文 247 Pages
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
デング熱ワクチンの市場規模：ワクチンタイプ・ ワクチンフェーズ・流通チャネル・地域別の展望・競合戦略・セグメント予測 (～2033年)
出版日: 2024年08月06日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 247 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のデング熱ワクチンの市場規模は、予測期間中にCAGR 13.11%で推移し、2033年には18億1,395万米ドルの規模に成長すると予測されています。

当レポートでは、世界のデング熱ワクチンの市場を調査し、市場概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 促進要因・抑制要因・機会・課題の分析
  • COVID-19の市場への影響

第5章 市場変数と見通し

  • SWOT分析
  • PESTEL分析
  • ポーターのファイブフォース分析
  • ヒートマップ分析

第6章 競合情勢

  • 製造拠点の分布・販売エリア・製品タイプ
  • M&A・提携・製品発売・協力

第7章 世界のデング熱ワクチン市場：ワクチンタイプ別

  • 世界市場の規模・シェア・予測
  • 生弱毒化ワクチン
  • 組み換えワクチン

第8章 世界のデング熱ワクチン市場：ワクチンフェーズ別

  • 世界市場の規模・シェア・予測
  • フェーズI
  • フェーズII
  • フェーズIII

第9章 世界のデング熱ワクチン市場：流通チャネル別

  • 世界市場の規模・シェア・予測
  • 合成
  • バイオベース

第10章 世界のデング熱ワクチン市場の予測

  • 市場規模・市場シェア

第11章 世界のデング熱ワクチン市場：地域別

  • 市場規模・市場シェアの推移・予測
  • アジア太平洋
  • 欧州
  • 中東・アフリカ
  • 北米
  • ラテンアメリカ

第12章 企業プロファイル

  • Butantan Institute
  • GeneOne Life Science Inc.
  • GlaxoSmithKline Plc
  • Mylan N.V.
  • Medigen Vaccine Biologics Corporation
  • Merck and Co. Inc.
  • Nunn's Home Medical Equipment Company Ltd.
  • Panacea Biotec Limited
  • Sanofi Pasteur Limited
  • Serum Institute of India Pvt. Ltd.

第13章 総論

第14章 略語一覧

第15章 参考リンク

目次
Product Code: PHAR2411

Dengue Vaccines Market Introduction and Overview

According to SPER Market Research, 'Dengue Vaccines Market Size- By Type of Vaccine, By Vaccine Phase, By Distribution Channel - Regional outlook, Competitive Strategies and Segment Forecast to 2033' States that the Global Dengue Vaccines Market is estimated to reach USD 1813.95 million by 2033 with a CAGR of 13.11 %.

Dengue vaccines are designed to prevent dengue fever, a tropical illness spread by Aedes mosquitoes. The primary challenge in developing these vaccines lies in addressing the four different dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4).

The focus on COVID-19 diverted resources, funding, and research efforts away from other infectious diseases, including dengue. This shift has slowed progress in the development and approval of new dengue vaccines.

Scope of the report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Type of Vaccine, By Vaccine Phase, By Distribution Channel

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Butantan Institute, GeneOne Life Science Inc., GlaxoSmithKline Plc, Mylan N.V., Medigen Vaccine Biologics Corporation, Merck and Co. Inc., Nunn's Home Medical Equipment Company Ltd., Panacea Biotec Limited, Sanofi Pasteur Limited, Serum Institute of India Pvt Ltd.

Global Dengue Vaccines Market Segmentation:

By Type of Vaccine: Based on the Type of Vaccine, Global Dengue Vaccines Market is segmented as; Live Attenuated Vaccines, Recombinant Vaccines.

By Vaccine Phase: Based on the Vaccine Phase, Global Dengue Vaccines Market is segmented as; Phase I, Phase II, Phase III.

By Distribution Channel: Based on the Distribution Channel, Global Dengue Vaccines Market is segmented as; Hospitals, Clinics, Retail Pharmacies.

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Dengue Vaccines Market

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Dengue Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type of Vaccine
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Dengue Vaccines Market

7. Global Dengue Vaccines Market, By Type of Vaccine (USD Million) 2020-2033

  • 7.1. Global Dengue Vaccines Market Size, Share and Forecast, By Type of Vaccine, 2020-2026
  • 7.2. Global Dengue Vaccines Market Size, Share and Forecast, By Type of Vaccine, 2027-2033
  • 7.3. Live Attenuated Vaccines
  • 7.4. Recombinant Vaccines

8. Global Dengue Vaccines Market, By Vaccine Phase (USD Million) 2020-2033

  • 8.1. Global Dengue Vaccines Market Size, Share and Forecast, By Vaccine Phase, 2020-2026
  • 8.2. Global Dengue Vaccines Market Size, Share and Forecast, By Vaccine Phase, 2027-2033
  • 8.3. Phase I
  • 8.4. Phase II
  • 8.5. Phase III

9. Global Dengue Vaccines Market, By Distribution Channel (USD Million) 2020-2033

  • 9.1. Global Dengue Vaccines Market Size, Share and Forecast, By Distribution Channel, 2020-2026
  • 9.2. Global Dengue Vaccines Market Size, Share and Forecast, By Distribution Channel, 2027-2033
  • 9.3. Synthetic
  • 9.4. Bio-Based

10. Global Dengue Vaccines Market Forecast, 2020-2033 (USD Million)

  • 10.1. Global Dengue Vaccines Market Size and Market Share

11. Global Dengue Vaccines Market, By Region, 2020-2033 (USD Million)

  • 11.1. Global Dengue Vaccines Market Size and Market Share By Region (2020-2026)
  • 11.2. Global Dengue Vaccines Market Size and Market Share By Region (2027-2033)
  • 11.3. Asia-Pacific
    • 11.3.1. Australia
    • 11.3.2. China
    • 11.3.3. India
    • 11.3.4. Japan
    • 11.3.5. South Korea
    • 11.3.6. Rest of Asia-Pacific
  • 11.4. Europe
    • 11.4.1. France
    • 11.4.2. Germany
    • 11.4.3. Italy
    • 11.4.4. Spain
    • 11.4.5. United Kingdom
    • 11.4.6. Rest of Europe
  • 11.5. Middle East and Africa
    • 11.5.1. Kingdom of Saudi Arabia
    • 11.5.2. United Arab Emirates
    • 11.5.3. Qatar
    • 11.5.4. South Africa
    • 11.5.5. Egypt
    • 12.5.6. Morocco
    • 11.5.7. Nigeria
    • 11.5.8. Rest of Middle-East and Africa
  • 11.6. North America
    • 11.6.1. Canada
    • 11.6.2. Mexico
    • 11.6.3. United States
  • 11.7. Latin America
    • 11.7.1. Argentina
    • 11.7.2. Brazil
    • 11.7.3. Rest of Latin America

12. Company Profile

  • 12.1. Butantan Institute
    • 12.1.1. Company details
    • 12.1.2. Financial outlook
    • 12.1.3. Product summary
    • 12.1.4. Recent developments
  • 12.2. GeneOne Life Science Inc.
    • 12.2.1. Company details
    • 12.2.2. Financial outlook
    • 12.2.3. Product summary
    • 12.2.4. Recent developments
  • 12.3. GlaxoSmithKline Plc
    • 12.3.1. Company details
    • 12.3.2. Financial outlook
    • 12.3.3. Product summary
    • 12.3.4. Recent developments
  • 12.4. Mylan N.V.
    • 12.4.1. Company details
    • 12.4.2. Financial outlook
    • 12.4.3. Product summary
    • 12.4.4. Recent developments
  • 12.5. Medigen Vaccine Biologics Corporation
    • 12.5.1. Company details
    • 12.5.2. Financial outlook
    • 12.5.3. Product summary
    • 12.5.4. Recent developments
  • 12.6. Merck and Co. Inc.
    • 12.6.1. Company details
    • 12.6.2. Financial outlook
    • 12.6.3. Product summary
    • 12.6.4. Recent developments
  • 12.7. Nunn's Home Medical Equipment Company Ltd.
    • 12.7.1. Company details
    • 12.7.2. Financial outlook
    • 12.7.3. Product summary
    • 12.7.4. Recent developments
  • 12.8. Panacea Biotec Limited
    • 12.8.1. Company details
    • 12.8.2. Financial outlook
    • 12.8.3. Product summary
    • 12.8.4. Recent developments
  • 12.9. Sanofi Pasteur Limited
    • 12.9.1. Company details
    • 12.9.2. Financial outlook
    • 12.9.3. Product summary
    • 12.9.4. Recent developments
  • 12.10. Serum Institute of India Pvt. Ltd.
    • 12.10.1. Company details
    • 12.10.2. Financial outlook
    • 12.10.3. Product summary
    • 12.10.4. Recent developments

13. Conclusion

14. List of Abbreviations

15. Reference Links